Journal of Gastroenterology

, Volume 45, Issue 10, pp 1053–1062

Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis

  • Paolo Sorrentino
  • Luigi Terracciano
  • Salvatore D’Angelo
  • Umberto Ferbo
  • Alessandra Bracigliano
  • Luciano Tarantino
  • Alessandro Perrella
  • Oreste Perrella
  • Giovanni De Chiara
  • Luigi Panico
  • Noè De Stefano
  • Mariolina Lepore
  • Raffaela Vecchione
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

Factors responsible for the progression of primary biliary cirrhosis (PBC) are still poorly understood. In the present study, we investigated the associations between the stage of PBC and the immune reaction triggered by oxidative stress; the presence of obesity, steatosis, steatohepatitis; and other toxic, metabolic, or steatogenic factors.

Methods

We studied clinical, laboratory, and histological data for 274 untreated patients with serum antimitochondrial antibody (AMA)-positive PBC. Circulating IgG against human serum albumin adducted with malondialdeyde, the major product of lipid peroxidation, was measured in these patients and in a group of 98 sex-, age- and body mass index (BMI)-matched controls.

Results

Steatosis was present in 40.5% of all patients. Steatohepatitis was present in 14.9% of all patients. There was a significant association between the frequencies of steatosis and steatohepatitis and the worsening of PBC. Circulating IgG against lipid peroxidation products was significantly higher in the PBC patients than in the controls. Titers of lipid peroxidation-related antibodies were significantly increased in patients with steatosis and in patients at more advanced stages. Bivariate analysis revealed a significant association between indirect evidence of oxidative stress, steatosis, steatohepatitis, age, BMI, frequency of diabetes, alcohol intake, iron grade after Perl’s stain, and PBC stage. Logistic regression analysis confirmed that the titers of antibodies against lipid peroxidation products (odds ratio 4.5, p < .001, 95% confidence interval 3.9–14.4), the presence of steatosis (odds ratio 4.1, 95% confidence interval 2.5–15.4, p < .001), higher BMI (odds ratio 3.9, p < .021, 95% confidence interval 1.4–9.5), and alcohol intake (males ≥ 30 g/day, females ≥ 20 g/day, odds ratio 4.5, 95% confidence interval 1.3–19.8, p < .029) were independently associated with more advanced stages of the disease.

Conclusions

The immune reactions triggered by oxidative stress, steatosis, obesity, and alcohol intake are independent predictors of PBC stage progression.

Keywords

Autoimmune cholangitis Primary biliary cirrhosis Oxidative stress Lipid peroxidation Steatosis BMI Alcohol Iron Obesity 

References

  1. 1.
    Sasaki M, Ikeda H, Nakanuma Y. Activation of ATM signaling pathway is involved in oxidative stress-induced expression of mito-inhibitory p21WAF1/Cip1 in chronic non-suppurative destructive cholangitis in primary biliary cirrhosis: an immunohistochemical study. J Autoimmun. 2008;31:73–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med. 2000;21:49–98.CrossRefPubMedGoogle Scholar
  3. 3.
    Suriawinata A, Fiel MI. Liver pathology in obesity. Semin Liver Dis. 2004;24:363–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. HCV Meta-Analysis (on) Individual Patients’ Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Rolla R, Vay D, Mottaran E, Parodi M, Traverso N, Aricó S, Sartori M, et al. Detection of circulating antibodies against malondialdehyde–acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology. 2000;31:878–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005;54:987–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Vidali M, Tripodi MF, Ivaldi A, Zampino R, Occhino G, Restivo L, et al. Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C. J Hepatol. 2008;48:399–406.CrossRefPubMedGoogle Scholar
  8. 8.
    Tuma DJ. Role of malondialdehyde–acetaldehyde adducts in liver injury. Free Radic Biol Med. 2002;15(32):303–8.CrossRefGoogle Scholar
  9. 9.
    Thiele GM, Tuma DJ, Willis MS, Miller JA, McDonald TL, Sorrell MF, et al. Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant. Alcohol Clin Exp Res. 1998;22:1731–9.PubMedGoogle Scholar
  10. 10.
    Rigamonti C, Mottaran E, Reale E, Rolla R, Cipriani V, Capelli F, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology. 2003;38:42–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Searle JW, Kerr JFR, Halliday JW, Powell LW. Iron storage disease. In: MacSween RNM, Anthony PP, Scheuer PJ, editors. Pathology of the liver. 3rd ed. Edinburgh: Churchill Livingstone; 1994. p. 257–72.Google Scholar
  13. 13.
    Portmann BC, Nakanuma Y. Disease of the bile duct. In: MacSween RNM, Anthony PP, Scheuer PJ, editors. Pathology of the liver. 3rd ed. Edinburgh: Churchill Livingstone; 1994. p. 435–506.Google Scholar
  14. 14.
    Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28:296–301.CrossRefPubMedGoogle Scholar
  15. 15.
    Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.CrossRefPubMedGoogle Scholar
  16. 16.
    Alptekin N, Mehmetçik G, Uysal M, Aykaç-toker G. Evidence for oxidative stress in the hepatic mitochondria of bile duct ligated rats. Pharmacol Res. 1997;36:243–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Karadeniz G, Acikgoz S, Tekin IO, Tascýlar O, Gun BD, Cömert M. Oxidized low-density-lipoprotein accumulation is associated with liver fibrosis in experimental cholestasis. Clinics (Sao Paulo). 2008;63:531–40.Google Scholar
  18. 18.
    Cömert M, Tekin IO, Acikgöz S, Ustündağ Y, Uçan BH, Acun Z, et al. Experimental bile-duct ligation resulted in accumulation of oxidized low-density lipoproteins in BALB/c mice liver. J Gastroenterol Hepatol. 2004;19:1052–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346:987–90.CrossRefPubMedGoogle Scholar
  20. 20.
    Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–64.CrossRefPubMedGoogle Scholar
  21. 21.
    Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578–84.CrossRefPubMedGoogle Scholar
  23. 23.
    Wyatt J, Baker H, Prasad P, Gong YY, Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol. 2004;57:402–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Bellentani S, Bedogni G, Miglioli L, Tiribelli C. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol. 2004;16:1087–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.CrossRefPubMedGoogle Scholar
  26. 26.
    Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest. 2004;113:1277–87.PubMedGoogle Scholar
  27. 27.
    Pessayre D, Fromenty B. NASH: a mitochondrial disease. J Hepatol. 2005;42:928–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100:850–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Comporti M, Arezzini B, Signorini C, Vecchio D, Gardi C. Oxidative stress, isoprostanes and hepatic fibrosis. Histol Histopathol. 2009;24:893–900 (Review).PubMedGoogle Scholar
  30. 30.
    Urtasun R, Conde de la Rosa L, Nieto N. Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis. 2008;12:769–90 (Review).CrossRefPubMedGoogle Scholar
  31. 31.
    Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, et al. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal. 2004;6:19–24.CrossRefPubMedGoogle Scholar
  32. 32.
    Niemelä O. Acetaldehyde adducts in circulation. Novartis Found Symp. 2007;285:183–92 (Review).CrossRefPubMedGoogle Scholar
  33. 33.
    Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther. 2005;22(Suppl 2):71–3 (Review).CrossRefPubMedGoogle Scholar
  34. 34.
    Eboumbou C, Steghens JP, Abdallahi OM, Mirghani A, Gallian P, van Kappel A, et al. Circulating markers of oxidative stress and liver fibrosis in Sudanese subjects at risk of schistosomiasis and hepatitis. Acta Trop. 2005;94:99–106.CrossRefPubMedGoogle Scholar
  35. 35.
    Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res. 2005;33:132–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1–28.CrossRefPubMedGoogle Scholar
  37. 37.
    Berson A, De Beco V, Lettéron P, Robin MA, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology. 1998;114:764–74.CrossRefPubMedGoogle Scholar
  38. 38.
    Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest. 1995;96:2461–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Trinder D, Ayonrinde OT, Olynyk JK. HCV, iron, and oxidative stress: the new choreography of hepcidin. Gastroenterology. 2008;134:348–51.CrossRefPubMedGoogle Scholar
  40. 40.
    Ono M, Sekiya C, Ohhira M, Ohhira M, Namiki M, Endo Y, et al. Elevated level of serum Mn-superoxide dismutase in patients with autoimmune cholangitis: possible involvement of free radicals in the pathogenesis in autoimmune cholangitis. J Lab Clin Med. 1999;118:476–83.Google Scholar
  41. 41.
    Kadokawa Y, Ohba K, Omagari K, Akazawa S, Hayashida K, Ohnita K, et al. Intracellular balance of oxidative stress and cytoprotective molecules in damaged interlobular bile ducts in autoimmune hepatitis and autoimmune cholangitis: in situ detection of 8-hydroxydeoxyguanosine and glutathione-S-transferase-pi. Hepatol Res. 2007;37:620–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Salunga TL, Cui ZG, Shimoda S, Zheng HC, Nomoto K, Kondo T, et al. Oxidative stress-induced apoptosis of bile duct cells in autoimmune cholangitis. J Autoimmun. 2007;29:78–86.CrossRefPubMedGoogle Scholar
  43. 43.
    Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol. 1995;22:449–56.CrossRefPubMedGoogle Scholar
  44. 44.
    Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C. Am J Gastroenterol. 2008;103(1):147–53.PubMedGoogle Scholar
  45. 45.
    Stewart SF, Vidali M, Day CP, Albano E, Jones DE. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology. 2004;39(1):197–203.CrossRefPubMedGoogle Scholar
  46. 46.
    Albano E. Free radical mechanisms in immune reactions associated with alcoholic liver disease. Free Radic Biol Med. 2002;15:110–4.CrossRefGoogle Scholar
  47. 47.
    Schneiderhan W, Schmid-Kotsas A, Zhao J, Grünert A, Nüssler A, Weidenbach H, et al. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology. 2001;34:729–37.CrossRefPubMedGoogle Scholar
  48. 48.
    Viñas O, Bataller R, Sancho-Bru P, Ginès P, Berenguer C, Enrich C, et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology. 2003;38:919–29.PubMedGoogle Scholar
  49. 49.
    Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;9:299–314.CrossRefPubMedGoogle Scholar
  50. 50.
    Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafiadis G, et al. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis. Acta Gastroenterol Belg. 2008;71:355–60.PubMedGoogle Scholar
  51. 51.
    van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12:805–24.CrossRefPubMedGoogle Scholar
  52. 52.
    Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:370–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Oza N, Nakashita S, et al. Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation. Liver Int. 2009;29:213–20.CrossRefPubMedGoogle Scholar
  54. 54.
    Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology. 2008;15:91–101.CrossRefPubMedGoogle Scholar
  55. 55.
    Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, LIDO Study Group, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) trial. Gastroenterology. 2008;135:100–10.CrossRefPubMedGoogle Scholar
  56. 56.
    Burkitt MJ, Mason RP. Direct evidence for in vivo hydroxyl-radical generation in experimental iron overload: an ESR spin-trapping investigation. Proc Natl Acad Sci USA. 1991;88:8440–4.CrossRefPubMedGoogle Scholar
  57. 57.
    Kadiiska MB, Burkitt MJ, Xiang QH, Mason RP. Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. J Clin Invest. 1995;96:1653–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Houglum K, Filip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest. 1990;86:1991–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology. 1995;109:1941–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Houglum K, Ramm GA, Crawford DH, Witztum JL, Powell LW, Chojkier M. Excess iron induces hepatic oxidative stress and transforming growth factor β 1 in genetic hemochromatosis. Hepatology. 1997;26:605–10.CrossRefPubMedGoogle Scholar
  61. 61.
    Pietrangelo A, Gualdi R, Casalgrandi G, Montosi G, Ventura E. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. J Clin Invest. 1995;95:1824–31.CrossRefPubMedGoogle Scholar
  62. 62.
    Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103:1036–42.CrossRefPubMedGoogle Scholar
  63. 63.
    Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol. 2002;282:G1–5.PubMedGoogle Scholar
  64. 64.
    Cheung O, Sanyal AJ. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:351–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol. 1996;24:200–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Paolo Sorrentino
    • 1
    • 4
  • Luigi Terracciano
    • 2
  • Salvatore D’Angelo
    • 1
  • Umberto Ferbo
    • 3
  • Alessandra Bracigliano
    • 4
  • Luciano Tarantino
    • 5
  • Alessandro Perrella
    • 6
    • 7
  • Oreste Perrella
    • 8
  • Giovanni De Chiara
    • 3
  • Luigi Panico
    • 3
    • 4
  • Noè De Stefano
    • 3
  • Mariolina Lepore
    • 3
    • 4
  • Raffaela Vecchione
    • 4
  1. 1.Liver Unit, Clinical and Experimental Hepatology, Department of Internal MedicineS.G. Moscati HospitalAvellinoItaly
  2. 2.Institute of PathologyUniversity of BaselBaselSwitzerland
  3. 3.Institute of PathologyS.G. Moscati HospitalAvellinoItaly
  4. 4.Department of Biomorphological ScienceFederico II University of NaplesNaplesItaly
  5. 5.Hepatology and Interventional Ultrasound Unit S. Giovanni di Dio HospitalNaplesItaly
  6. 6.Department of Infectious DiseaseUniversity of NaplesNaplesItaly
  7. 7.Department of Laparoscopic, Hepatic Surgery and Liver Transplant UnitA. Cardarelli HospitalNaplesItaly
  8. 8.VII Department of Infectious Diseases and ImmunologyD. Cotugno HospitalNaplesItaly

Personalised recommendations